Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2023

	*Nine Months Ended September 30,*
	*2023*		*2022*
Balance at beginning of period	$	563	$	(17	)
Net unrealized gain on foreign currency translation		170		1,503
Balance at end of period	$	733	$	1,486